Sign In
News Digest /
Ticker: LLY
Ticker: LLY
05:03am, Monday, Aug 19, 2024
Eli Lilly's Zepbound, a groundbreaking GLP-1 agonist, is quickly becoming a blockbuster, complementing Mounjaro and competing with Novo Nordisk. With the obesity treatment market expected to reach $100 billion by 2030, Eli Lilly is a compelling long-term investment.
07:13am, Thursday, Aug 08, 2024
Eli Lilly (NYSE: LLY) raises 2024 profit forecasts following Zepbound's record $1B quarterly sales. With a 32% stock surge this year and aggressive production plans, Eli Lilly is poised for growth in the booming weight-loss market. Investors should watch closely.
03:36am, Wednesday, Aug 07, 2024
Novo Nordisk (NYSE: NVO) reported mixed Q2 results, raising its 2024 sales forecast but falling short on operating profit amid rising competition from Eli Lilly in the obesity sector. Traders should stay alert to this evolving market landscape.
06:01am, Monday, Aug 05, 2024
Kinaxis Inc. (NYSE: KXS) reported strong Q2 2024 results, with SaaS revenue up 18% to $75.4 million and total revenue rising 12% to $118.3 million. However, challenges like contract delays and election uncertainty could impact future growth. Long-term outlook remains positive.
03:37am, Friday, Jul 26, 2024
Eli Lilly & Co. (NYSE: LLY) faces a $120 billion market cap loss as rivals advance in the obesity drug space. With a stock drop of 14% in eight days, analysts warn of looming challenges despite a positive year-to-date. The upcoming earnings report could be pivotal.
07:25am, Monday, Jul 08, 2024
Eli Lilly (NYSE: LLY) acquires Morphic Holding (NASDAQ: MORF) for $3.2B, aiming to enhance IBD treatment innovations. Morphic's shares surged 76% premarket, driven by the 79% premium offer. Ongoing phase 2 trials of MORF-057 are key for traders to watch.
08:57am, Wednesday, Jul 03, 2024
Wednesday Markets: S&P 500 and Nasdaq hit new records, Fed comments on inflation, FDA approves Alzheimer’s drug, and ADP reports June payroll growth slowdown.
04:53am, Wednesday, Jul 03, 2024
The FDA has approved Eli Lilly's (NYSE: LLY) new Alzheimer's treatment, Kisunla, for early-stage patients, marking it as the second therapy in the U.S. to slow Alzheimer's progression. Priced at $32,000 annually, Kisunla is expected to achieve over $5 billion in peak sales.
04:42am, Monday, Jul 01, 2024
Sanofi (NASDAQ: SNY) plans a $1.6 billion investment in its Frankfurt, Germany facility, marking a significant shift from its earlier French production plans. This move, following major investments by Daiichi Sankyo and Eli Lilly in Germany, highlights the country's growing pharmaceutical appeal.